Natco Pharma's Vishakapatanam unit issued 2 observations by USFDA

Natco Pharma's Vishakapatanam unit issued 2 observations by USFDA

According to Natco Pharma, the business is certain that it can address every observation in the allotted period

FPJ Web DeskUpdated: Saturday, February 04, 2023, 03:58 PM IST
article-image
Natco Pharma's Vishakapatanam unit issued 2 observations by USFDA | Image: Natco Pharma (Representative)

Natco Pharma Ltd today said that the US Food and Drug Administration has issued two observations to its formulation facility in Ramky SEZ, in Visakhapatnam after the regulator conducted an inspection, in an exchange filing.

"At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure," the company said in the filing.

The inspection took place from January 30 to February 3. According to Natco Pharma, the business is certain that it can address every observation in the allotted period.

The pharmaceutical business in Hyderabad creates, produces, and markets completed dosage formulations and active pharmaceutical components in nations including India, the US, and Europe.

RECENT STORIES

Bank Of India Faces ₹564 Crore Penalty From Income Tax Department; Yes Bank Also Hit With ₹113...

Bank Of India Faces ₹564 Crore Penalty From Income Tax Department; Yes Bank Also Hit With ₹113...

The Impact Of AI On Psychometric Testing

The Impact Of AI On Psychometric Testing

Shapoorji Pallonji Group's Afcons Infrastructure Files Draft Red Herring Prospectus For ₹7,000 Cr...

Shapoorji Pallonji Group's Afcons Infrastructure Files Draft Red Herring Prospectus For ₹7,000 Cr...

ICICI Securities' Retail Distribution Head Quits; Exchange Filing Reveals

ICICI Securities' Retail Distribution Head Quits; Exchange Filing Reveals

Exploring The Technological Foundation Of Harambe Token

Exploring The Technological Foundation Of Harambe Token